 Latest
News
Archive
| January 2020 |
MBC Pharma, Inc. initiates a clinical trial of GEM-IB in combination with docetaxel in dogs with spontaneous osteosarcoma.
|
| July 15-17, 2019 |
MBC Pharma Inc. presents Phase I MBC-11 clinical results with PK and 2nd generation lead compound GEM-IB in vivo efficacy at the Bisphosphonates 2019: celebrating 50 years meeting in Sheffield, UK
(poster presentation)
|
| March 2019 |
MBC Pharma Inc. publishes results of MBC-11 Phase I clinical trial demonstrating first-in-class human proof of concept in patients with metastatic bone disease.
|
| September 20, 2017 |
MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel
Bone-Targeted Combination Treatment for Osteosarcoma (read more) |
| August 16, 2017 |
MBC Pharma, Inc. awarded an SBIR Phase I grant to investigate novel compounds against osteomyelitis
(read more)
|
| October 27, 2014 |
MBC
Pharma and Osteros Biomedica announce initiation of Phase 1 clinical
trial of MBC-11 in patients with cancer induced bone disease (read more)
|
| September 19, 2012 |
MBC Pharma and Maxwell Biotech Group partner to clinically develop a new anti-tumor drug candidate
MBC-11 targeting metastatic bone disease
(read more)
|
| May 25, 2012 |
MBC Pharma, Inc. wins a legal battle against Cedarburg Hauser Pharmaceuticals (read more)
|
|
|
|
Key
Publications
- Farrell, K.B., Zinnen, S.P., Thamm, D.H., Karpeisky, A. (2021) Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel. Bioconjug. Chem., 32, 12, 2530-2539 PubMed PMID: 34779607; PubMed Central PMCID: PMC9773925.
- Zinnen, S.P., Karpeisky, A., Von Hoff, D.D., Plekhova, L., Alexandrov, A. (2019) First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist, 24 3, 303-e102 PubMed PMID: 30413669; PubMed Central PMCID: PMC6519757.
- Farrell, K.B., Karpeisky, A., Thamm, D.H., Zinnen, S. (2018) Bisphosphonate conjugation for bone specific drug targeting Bone Rep., 9 , 47-60 PubMed PMID: 29992180; PubMed Central PMCID: PMC6037665.
- Reinholz,
M. M., Zinnen, S. P., Dueck, A. C., Dingli, D., Reinholz, G. G.,
Jonart, L. A., Kitzmann, K. A., Bruzek, A. K., Negron, V., Abdalla, A.
K., Arendt, B. K., Croatt, A. J., Sanchez-Perez, L., Sebesta, D. P.,
Lonnberg, H., Yoneda, T., Nath, K. A., Jelinek, D. F., Russell, S. J.,
Ingle, J. N., Spelsberg, T. C., Dixon, H. B., Karpeisky, A., Lingle, W.
L., (2010),A promising approach for treatment of tumor-induced bone
diseases: Utilizing bisphosphonate derivatives of nucleoside
antimetabolites Bone , 47 73, 12-22
- Mikko Ora, Tuomas Lonnberg, Diana Florea-Wang, Shawn
Zinnen,Alexander Karpeisky, and Harri Lonnberg (2008)
Bisphosphonate Derivatives of Nucleoside Antimetabolites:
Hydrolytic Stability and Hydroxyapatite Adsorption of
5′-β,γ-Methylene and
5′-β,γ-(1-Hydroxyethylidene) Triphosphates of
5-Fluorouridine and ara-Cytidine. JOC,
73,
4123-30
- Zinnen,
S.,Sebesta, D., Karpeisky, A., Guzaev, A., (2006) Novel vitamin B6
derivative of alendronate rapidly absorbed following oral
administration. Bone 38, S64
- Reinholz,
M., Reinholz, G., Arendt, B., Jelinek, D., Kitzmann, K., Dingli, D.,
Russel, S., W., L., and Karpeisky, A. (2005). Novel bisphosphonate
conjugates inhibit multiple myeloma cell proliferation in vitro and
increase bone mineral density and prolong survival in a mouse multiple
myeloma model. Cancer Treatment Reviews 31, abstract
# 119.
- Reinholz,
M., Reinholz, G., Jonart, L., Yoneda, T., Spelsberg, T., Lingle, W.,
and Karpeisky, M. (2004). Novel bisphosphonate conjugates decrease
metastatic bone tumor burden in the 4T1/luc mouse model of breast
cancer. Journal of Bone and Mineral Research 19, S66.
- Reinholz,
M., Jonart, L., Reinholz, G., Spelsberg, T., Lingle, W., Yoneda, T.,
and Karpeisky, M. (2004). The effects of novel bisphosphonate
conjugates on primary breast tumor burden and soft organ metastases in
the 4T1/luciferase mouse model of breast cancer. Breast Cancer
Research and Treatment 88, S133.
- Reinholz,
G.G., Getz, B., Sanders, E.S., Karpeisky, M.Y., Padyukova, N.,
Mikhailov, S.N., Ingle, J.N., and Spelsberg, T.C. (2002). Distinct
mechanisms of bisphosphonate action between osteoblasts and breast
cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Research and Treatment 71,
257-268
|
|
